Condition
Precursor B-Cell Lymphoblastic Leukemia
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Terminated2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06554626Phase 2RecruitingPrimary
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL
NCT01483690Phase 1Terminated
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
NCT01761682Terminated
Acute Lymphoblastic Leukemia Registry at Asan Medical Center
Showing all 3 trials